Repository logo

Browsing by Author "Basaraba, Randall, advisor"

Now showing 1 - 3 of 3
  • Thumbnail Image
    ItemOpen Access
    Host directed therapy targeting M. tuberculosis infected macrophages
    (Colorado State University. Libraries, 2016) Lakey, Natalie, author; Basaraba, Randall, advisor; Podell, Brendan, committee member; Perera, Rushika, committee member; Chicco, Adam, committee member
    With the rise of drug resistant strains of Mycobacterium tuberculosis (Mtb) and lags in antimicrobial drug development, it is imperative to explore alternative methods of treatment through host-directed adjunct therapies. Hallmarks of Mtb infection are altered host cell glucose metabolism and non-diabetic hyperglycemia, which increase disease severity and bacterial burden. This can be targeted using a combination of metformin and 2-deoxyglucose (2DG) to lower systemic blood glucose and increase metabolic stress in infected macrophages to induce apoptotic cell death, enabling Mtb clearance and antigen presentation to activate cell-mediated immune responses. We hypothesized that bacterial survival is aided by glycolysis-dependent macrophages, which can be targeted using a combination of metformin and 2DG to strengthen host immune responses. Using an in vitro model of guinea pig bone marrow derived macrophages under normal and high glucose conditions, we determined that both basal respiration and glycolytic activity increased after infection. When singly treated, metformin inhibited basal respiration while increasing glycolysis while 2DG inhibited both processes. In combination metformin and 2DG treatment inhibited basal respiration more effectively than metformin treatment alone and inhibited glycolysis as effectively as 2DG by itself. Efficacy of metformin-2DG treatment is dependent on high cellular glycolytic activity, a characteristic of granulomatous cells. Metformin-2DG treatment decreased cell survival 48 hours post-treatment by increasing apoptotic cell death and decreased Mtb survival more effectively than metformin or 2DG alone. We conclude that apoptotic induction of macrophages by metformin-2DG treatment may be a viable adjunct treatment to antimicrobial drugs to reduce bacterial burden and increase an effective host adaptive immune response.
  • Thumbnail Image
    ItemOpen Access
    Metabolic interventions in the treatment of Mycobacterium tuberculosis infection
    (Colorado State University. Libraries, 2023) Ackart, David, author; Basaraba, Randall, advisor; Podell, Brendan, committee member; Chicco, Adam, committee member
    Tuberculosis remains a global threat. For the first time in over a decade, there was an increase in deaths in 2021. Current antimicrobial treatments are lengthy and costly, which leads to non-compliance. Host-directed therapies have emerged as a possible adjuvant to antimicrobial treatment. It has become clear that immune cell function and metabolic pathways are intertwined and a target for therapy. Previously, metformin, a partial inhibitor of complex I, was associated with decreased disease burden in the guinea pig model. Based on these findings, we hypothesized that limiting glycolysis would reduce lesion burden and bacterial viability. To test our hypothesis, we infected guinea pigs for thirty days and then administered metformin or 2-deoxy-glucose alone, and in combination. After 90 days of infection, histological analysis revealed increased healing in the combination treatment. To determine the effect of treatment on cellular metabolism, we evaluated treatments in guinea pig bone marrow-derived macrophages. We found that the combination treatment reduced bacterial viability, prevented mitochondrial damage, and increased apoptosis, which helps support in vivo findings. These findings suggest that the metabolic switch of immune cells to glycolysis alone is insufficient to control Mycobacterium tuberculosis infection; it is essential, as is oxidative phosphorylation.
  • Thumbnail Image
    ItemOpen Access
    Mycobacterium tuberculosis – mediated modulation of host macrophage metabolism in the granuloma microenvironment
    (Colorado State University. Libraries, 2020) Kiran, Dilara, author; Basaraba, Randall, advisor; Podell, Brendan, committee member; Obregon-Henao, Andres, committee member; Olver, Christine, committee member; Chicco, Adam, committee member
    Mycobacterium tuberculosis (Mtb) is the leading cause of death by an infectious agent, and tuberculosis (TB) disease continues to be a prominent global health concern. Infection with Mtb incites granulomatous inflammation, chronic antigen stimulation, and the development of granuloma lesions. These lesions compress tissue architecture in a way that reduces blood supply and creates central regions of hypoxia. Complex lesion pathology, multi-drug resistance of Mtb, co-morbidities with other endemic diseases, the lack of an effective vaccine, and slow drug development pipelines have hindered progress in the field. Researchers have worked to combat these difficulties through their exploration of host-directed therapeutic strategies, which aim to better equip the host immune system to respond to Mtb infection, with a focus on immunometabolism as a target pathway. The metabolism of host macrophages plays a role in modulating disease pathogenesis, with a metabolic switch from oxidative phosphorylation to glycolysis characterizing Mtb infected macrophages. This metabolic switch is primarily regulated at the transcriptional level by hypoxia inducible factor-1α (HIF-1α), which regulates the cellular response to hypoxic stressors encountered within the chronic granuloma lesion microenvironment. Downstream impacts of HIF-1α activation include increased glycolysis, increased lactate production, and increased lactate transport. HIF-1α becomes stable and undergoes its transcriptional activity in conditions of low oxygen, as a result of prolyl hydroxylase (PHD) inhibition. Additionally, hypoxia-independent factors interfere with PHD leading to HIF-1α stabilization, including iron chelation. Bacteria, such as Mtb, have developed iron chelating siderophores to sequester iron from host cells, and knocking-out these iron chelators has been demonstrated to reduce stable HIF-1α activation. As a result, we hypothesized that the Mtb siderophore, mycobactin, plays a role in driving stabilization of HIF-1α during early infection, prior to the development of hypoxic lesion microenvironments. This would serve as a pathogen-driven mechanism that would support macrophage adaptation to hypoxia later during disease progression, and thus develop an Mtb survival niche. Using purified iron chelators deferoxamine (DFO) and mycobactin J (MbtJ), we demonstrated that treated CD1 mouse bone marrow derived macrophages (BMDMs) increase HIF-1α via Western Blot and potently increase glycolytic metabolism as demonstrated by Seahorse Extracellular Flux Analysis. Additionally, the use of mycobactin synthase K (mbtK) knock-out, complement, or wild-type H37Rv strains of Mtb demonstrated the role that mycobactin plays in the metabolic response of macrophages in vitro, having a significant impact on oxidative metabolism. Hypoxia-independent mechanisms of HIF-1α activation by mycobactin may be a critical pathway through which Mtb drives macrophages toward a phenotype conducive for bacterial survival. Lactate produced as a result of increased glycolytic metabolism during infection may also play an important role as a metabolic intermediate and as a signaling molecule during Mtb infection. Metabolic symbioses exist in multiple systems between highly glycolytic, hypoxic cells and more oxidative, normoxic cells, wherein glycolytic cells uptake glucose, convert glucose to lactate via lactate dehydrogenase (LDHA) and export lactate in large amounts via monocarboxylate transporter 4 (MCT4). Normoxic cells import lactate via monocarboxylate transporter 1 (MCT1) and convert it back to pyruvate via lactate dehydrogenase B (LDHB) and utilize lactate-derived pyruvate to fuel mitochondrial respiration. This preserves glucose for hypoxic cells which rely heavily on glycolysis for metabolic survival. While this type of lactate shuttle has been demonstrated to regulate the tumor microenvironment, it has yet to be explored within the context of the similar TB granuloma microenvironment. As a result, we explored the role of a lactate shuttle within Mtb infection by detecting lactate in guinea pig plasma, detecting lactate shuttle components within guinea pig granuloma lesions, and by using the LDHA inhibitor sodium oxamate and the MCT1 inhibitor α-Cyano-4-hydroxycinnamic acid (α-CHC), both of which are commercially available. We showed that Mtb infection significantly increases lactate on both a systemic and cellular level. We successfully demonstrated that LDH and MCT inhibition augments metabolism in macrophages by blocking glycolysis and decreasing mitochondrial spare capacity. Through in vitro Mtb infection models, we were able to show that inhibitor treatment can reduce the amount of lactate accumulated. These studies demonstrated proof of concept for the role of a lactate shuttle in modulating macrophage metabolism during Mtb infection and maintaining infection dynamics within the granuloma microenvironment. Overall, the research presented herein seeks to understand the ways in which Mtb infection drives host macrophages to alter their metabolic phenotype in a way that promotes Mtb survival and contributes to disease pathogenesis. A better understanding of the interactions which occur at the host-pathogen interface will provide important insight for the development of host-directed therapeutic strategies which will better equip host cells to combat Mtb infection.